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Secondary metabolites from plants, animals and microorganisms
have been proven to be an outstanding source for new and
innovative drugs and show a striking structural diversity that
supplements chemically synthesized compounds or libraries in drug
discovery programs. Unfortunately, extracts from natural sources
are usually complex mixtures of compounds: often generated in
time consuming and for the most part manual processes. As quality
and quantity of the provided samples play a pivotal role in the
success of high-throughput screening programs this poses serious
problems. In order to make samples of natural origin competitive
with synthetic compound libraries, we devised a novel, automated
sample preparation procedure based on solid-phase extraction
(SPE). By making use of a modi￿ed Zymark RapidTrace1
SPE workstation an easy-to-handle and eå ective fractionation
method has been developed which allows the generation of high-
quality samples from natural origin, ful￿lling the requirements of
an integration into high-throughput screening programs.
Introduction
Concepts to improve the generation and identi® cation of
lead structures are key issues in the development of new
pharmaceuticals and agro-chemicals. In the early stages
of drug discovery high sample numbers are requested to
feed the current capacities of the high-throughput screen-
ing (HTS) machinery. At present, compound libraries
from combinatorial chemistry are the major source for
HTS programs. On the other hand, however, nature has
been proven to be an outstanding source for new and
innovative drugs[1]. Numerous examples from medicine,
such as cyclosporin A, lovastatin, acarbose, paclitaxel,
FK506, topotecan, or miglitol, impressively demonstrate
the innovative potential of natural products regarding
their impact on progress in drug discovery and their
importance on the drug market [1]. At present, natural
products and substances derived from the account for
about 30% of the worldwide sales of drugs and 9 of the
top 20 best selling drugs.
Secondary metabolites from plants, animals and micro-
organisms show a striking structural diversity and supple-
ment chemically synthesized compound collections or
libraries in drug discovery programs. We presume that
the molecular understanding of complex biological com-
munication networks will have a dramatically in¯ uence
on the discovery processes of new drugs (® gure 1) [2].
Hypothetically, diseases correlated to complex molecular
interactions a￿ ord structurally more complex drug
candidates which points to the evolutionary proven,
stereochemically de® ned, and, in comparison with com-
binatorials, often structurally more complex natural
products.
Access to structural diversity from Nature
For a number of reasons natural products passed through
a phase of reduced interest in drug discovery strategies
(® gure 2). As only a few thousand pure natural com-
poundsare available for screening, there isa need for new
and more e￿ cient strategies to access structural diversity
from Nature. At present, strategies to improve the tech-
niques for isolation and structural characterization of
natural products are far from obtaining hundreds of
thousands of well characterized pure compounds [3],
because the identi® cation, puri® cation and structural
characterization of individual compounds from complex
mixtures are cost- and time-consuming procedures. In
order to take advantage of biodiversity in combinatorial
chemistry, approaches to enhance natural products or to
direct a total synthesis of a natural product towards
combinatorial structure variation are currently under
way [4]. However, the latter strategies depend on the
availability of either pure or biologically striking natural
products. Therefore, at present, extracts from natural
sources play the major role in drug discovery from
Nature, but such samples have a number of di￿ culties
(see ® gure 2) as follows.
. Access to biological material from plants, microor-
ganisms, fungi, animals, etc. has to be quaranteed.
However, the amount of secondary metabolites
wanted may vary from sample to sample.
. Extracts from natural sources are often generated
in time-consuming and, for the most part, manual
processes.
. The extracts usually contain a complex mixture of
substances. These mixtures can result in overlap-
ping biological e￿ ects, especially in functional
assay systems. Thus, biologically active compounds
may be hidden or false-positive e￿ ects may result
from a combination of di￿ erent compounds, not
allowing reliable `go/no± go’ decisions for further
processing.
. Recognition and de-replication of known, already
isolated, or unwanted types of compound are often
not possible until a late stage of the investigative
process.
. Consistency and viscosity of the extracts are not well
suited for the requirements of automated liquid
handling systems.
Consequently, there exists a need for improving the
technologies of sample preparation from natural sources
in order to produce high-quality test samples with
less complexity and more reliable reproducibility. In
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http://www.tandf.co.uk /journals 149addition, the tedious, time-consuming and manual pro-
cesses of sample preparation have to be replaced to
provide samples of su￿ cient quality and quantity for
high-throughput screening programs.
The single-step solid-phase extraction approach
Our approach [5] evolved from a procedure for sample
preparation from microbial broths which had already
been developed for chemical screening [6]. This manual
one-step procedure works by adsorption of the secondary
metabolites present in the culture broth of microbial
cultivations on to polystyrene resins such as Amberlite
XAD-16 and elution with organic solvents to yield
concentrated complex mixtures of natural products
[7, 9]. In order to achieve a signi® cantly higher quality
of the samples, chromatographic fractionation on new
adsorption resins with enhanced chromatographic fea-
tures as well as higher adsorption capacities is of funda-
mental importance. The results below have been
achieved with modi® ed Zymark RapidTrace1 SPE
workstations.
Most critical for a high-resolution fractionation of com-
plex material from natural sources is the choice of the
solid-phase extraction (SPE) material. Making use of
Figure 1. Natural products: from biological activity to a molecular understanding of biological communication networks [2].
Figure 2. Challenges for drug discovery approaches with samples from natural sources.
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150both a single-step fractionation method that is followed
by a concentration step also based on SPE (® gure 3), and
a mixture of pure natural products with a broad range of
polarity a number of adsorption resins and reverse-phase
silica gel materials were evaluated. Among the resins
tested [5], ENV‡ showed the broadest spectrum of
adsorption, in combination with a well resolved chroma-
tographic separation of the compounds in the ® rst frac-
tionation step (® gure 4) [9].
On the basis of the ENV‡ adsorption resin a single-step
fractionation and concentration method was developed
and optimized which allows fractionation of the second-
ary metabolites present in 50ml of culture broth from
Actinomycetes and Fungi imperfecti (see ® gure 5) [9]. After
cultivation of the microorganisms the culture broth was
centrifuged and the supernatant was applied to ENV‡
(500mg). Then the resin was washed with water and the
secondary metabolites were eluted with increasing
Figure 3. Single-step SPE method used for the evaluation of the SPE-adsorption resins.
Figure 4. Separation of the mixture of natural products by single-step SPE fractionation and concentration with the adsorption resin
ENV‡ (International Sorbent Technology Ltd, Mid Glamorgan, UK).
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151amounts of methanol (20%, 40%, 60%, 70%, 80%, and
twice 100%). The obtained fractions were diluted with
water to yield methanol concentrations of about 2± 5%
which were pumped on to a second SPE column (50mg
of resin) for concentration. The best results concerning
the concentration of compounds were achieved if the
choice of SPE materials was adjusted to the elution
characteristic in the preceding fractionation. For those
fractions eluted from the ENV‡ resin with 50% or less
methanol, ENV‡ was most e￿ cient also for the sample
concentration procedure. The more lipophilic fractions,
eluted with more than 50% methanol, were best ad-
sorbed and eluted from RP-C8 material. After a washing
step with water, the adsorbed organic compounds were
eluted with ca. 500ml of organic solvent into sample vials
that ® tted into the 96-well plate format. In the last
elution step either methanol and other alcohols or even
DMSO (dimethylsulphoxide) can be used. Because of the
physico-chemical behaviour of each substance, the con-
centration factors vary from 4-times to 40-times[9]. With
slight variations in the handling parameters this pro-
cedure can also be adapted to the fractionation of other
organisms such as microalgae [10].
To acquire information about the sample quality from
the single-step SPE fractionation and concentration
method compared with the manual one-step procedure
without fractionation on Amberlite XAD-16 resin, a
number of culture broths from various microbial cultiva-
tions were analysed. In ® gure 6 the MALDI-TOF
mass spectrometry analysis of samples obtained from
Streptomyces sp. strain GT 61174 are depicted. The sample
obtained from the XAD-16 procedure showed ca. 15 to 20
di￿ erent metabolites while single-step fractionation and
concentration into seven extracts enriched the com-
pound, with m=z ˆ 474:8:
In addition, samples from single-step SPE fractionation
exhibit advantages in biological screening, especially for
the generation of e￿ cient `hit-lists’. On the basis of a
functional yeast-based transcription assay with the
human progesterone receptor [11], a number of samples
from the XAD-16 extraction method were screened for
biological activity and samples from the Streptomyces
strains GT 51237/2, GT 41186/2, and GT 41179/3
showed activity. In parallel, samples from the cultivation
of these strains obtained by single-step SPE fractionation
and concentration (resin: ENV‡) were prepared and
analysed. As depicted in ® gure 7, the recovery rates of
the biological activity in GT 51237/2 and in GT 41186/2
are nearly identical to those from the XAD-16 method,
while in the case of GT 41179/3 parts of the biologically
active principle remained on the SPE column. In our
studies some highly lipophilic compounds were found to
stick to the resin even when pure organic eluent was
usedÐ a disadvantage of the ENV‡ resin. In addition,
GT 41186/2 produces two di￿ erent biologically active
metabolites (elution with 40% and 100% methanol)
which, in principle, are not detectable in XAD-16
samples. A further advantage lies in the possibility of
the separation of wanted biological activity (here: inter-
action with the human progesterone receptor) from, for
example, toxic compounds, which further increases the
quality towards that of the hit-lists.
The multi-step single-phase extraction approach
In order to improve the separation quality towards pure
compounds, the SPE protocol was extended by a second
fractionation step. The focus lies on those cases where
more complex samples have to be handled or further
fractionation is desirable for identi® cation of biologically
active compounds. The developed procedure can be
outlined as follows (® gure 8). In a ® rst step, the aqueous
crude compound mixture is applied on to a ® rst SPE
cartridge. Fractions of the column are eluted by stepwise
Figure 5. Optimized method for single-step SPE fractionation and concentration of material from natural sources. SPE-I: chromatographic
fractionation with SPE resins. SPE-II: Sample concentration via SPE resins.
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spectrometry.
Figure 7. Quality analysis of samples prepared from the cultivation of Streptomyces strains via biological screening using a yeast-based
transcription assay with the human progesterone receptor [11].
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153application of water/organic solvent or bu￿ er/organic
solvent mixtures with an increasing content of organic
solvent. The fractions generated in this ® rst step can be
further fractionated by using an identical procedure.
However, before re-loading on to the next column, the
solution has to be diluted with water in order to decrease
its elution strength. As for the concentration step in the
single-step fractionation procedure the chromatographic
material has to be chosen according to the type of
fraction yielded from the ® rst separation. After the ® nal
fractionation, the samples need to be concentrated for
further processing, for example for integration into HTS.
Asan example, the culture ® ltrate of the fungal strain GT
076111 was fractionated according to the multi-step
SPE fractionation protocol. HPLC spectra (diode array
detector at a wavelength of 254nm) of representative
fractions illustrate the suitability of the method to
prepare samples of signi® cantly reduced complexity
(® gure 9). A spectrum of an extract prepared by a
single-step work-up procedure with Amberlite XAD-16
(® gure 9 (A)) is compared with spectra of fractionated
samples from the same strain prepared by automated
multi-step SPE (® gures 9 (B) and (C)). The multi-step
SPE protocol included two fractionations and one con-
centration step. Figure 9 (B) showsthe spectrum of one of
the fractions after the ® rst fractionation step. The eluent
was further fractionated and subsequently concentrated.
In 9 (C) the sample from 9 (B) has been submitted to an
additional fractionation step.
Automation with Zymark RapidTrace1 SPE
workstations
Automation of both the single-step and the multi-step
SPE protocols require the following features:
(i) handling of liquid volumes larger (e.g. 50ml) than
SPE machines usually allow,
(ii) fraction collection is necessary,
(iii) re-loading of fractions from the collection device
should be given,
(iv) the elution strength of fractions has to be reduced by
dilution with water or bu￿ er,
(v) elution volumes range from 5ml to 300ml, and
(vi) parallel handling should be possible.
A commercially available automation concept meeting
all these requirements was not available. Closest was the
Zymark RapidTrace1 SPE workstation, an apparatus
for automated SPE that has already been used as a stand-
alone machine for method development (see above).
Therefore, in close cooperation with Zymark GmbH
(Germany) a workstation consisting of eight RapidTrace
modules was re-designed according to our special re-
quirements.
The modi® cations were set up as depicted in ® gures 10
and 11. One module is used to perform the ® rst fractio-
nation step. Specially designed tube connectors mounted
into the standard tube rack provide samples for the other
seven modules. The eluted fractions of the ® rst fractiona-
tion are collected in special PTFE vessels, equipped with
a magnetic stirrer. These mixing chambers with a
capacity of 200ml replace the standard 6 ml chambers
and are used for dilution and solvent mixing, but also
serve as fraction collectors. With a pneumatically driven
vacuum generator these chambers can be set under low
vacuum to ensure complete emptying of the supply tubes.
After the ® rst fractionation step, further processing (frac-
tionation or concentration) of the samples is carried out
in parallel on up to nine RapidTrace modules (at pres-
ent, the number is limited by the control software). After
the concentration step special rack adapters allow the
Figure 8. Multi-step SPE for e￿ cient fractionation and concentration of material from natural sources making use of diå erent adsorption
resins.
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microplates.
Conclusion
Samples from natural sources prepared by the automated
single- and multi-step SPE fractionation methods were
successfully introduced into both our biological and our
physico-chemical screening programs [6]. In these
screening approaches reduced complexity of the applied
samples results in a strong gain in information. The
advantage of fractionated samples is particularly obvious
in biological screening. Assay results become more re-
liable and reproducible if not a complex mixture but
fractions of reduced complexity are submitted to HTS. In
addition, fractionation might separate toxic components
from interesting, biologically active ones [5, 9]. Figure 12
summarizes information about the quantity of samples
which can be prepared from microbial broths with one
modi® ed RapidTrace1 SPE workstation per year.
In our automation protocol the samples can be generated
without (in case of one fractionation and concentration
step) or with only minor manual intervention (changing
Figure 9. HPLC-DAD spectra (at 254nm) of samples obtained from the cultivation of the fungal strain GT 076111: (A) Amberlite
XAD-16 sample; (B) single-step fractionation; (C) multi (2)-step fractionation of sample (B).
Figure 10. The modi￿ed Zymark RapidTrace1 SPE work-
station developed for single-step and multi-step SPE fractionation
and concentration.
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155tube positions in the sample rack if two or more fractio-
nation steps are carried out). The set-up allows parallel
processing of samples after the ® rst fractionation step.
However, present commercially available devices for
parallel SPE in the 96-format, which is about to be a
routine technique in diagnostic sample preparation [11],
cannot be used for our method owing to the limited
possibilities of handling liquid volumes of more than 2ml
per sample. In order to make high-quality samples from
natural origin available in signi® cantly higher numbers
we are currently working on a concept to increase the
grade of parallel processing adjusted to our needs.
Figure 11. Schematic drawing of the modi￿ed Zymark RapidTrace1 SPE workstation. (a) Standard tube rack for 10sample tubes and 10
collection tubes; (b) SPE column turret (holds up to ten 1ml or 3ml SPE cartridges); (c) 12-port valve for the distribution of the liquid
￿ow.
Figure 12. Calculation of the capacity for high-quality sample preparation using the single-step SPE fractionation and concentration
method with one modi￿ed RapidTrace1 SPE workstation.
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